Experiments in BALB/C nu/nu mice bearing SKOV-3 demonstrated HER2-specific uptake of 18 F-FBO-E 3 -PEP4313 in tumors. At 2 h pi, the tumor uptake (20 ± 2 % ID/g) exceeded uptake in liver 5-fold and uptake in kidneys 3.6-fold. The tumor-to-blood ratio was 21±3. The microPET/CT imaging experiment confirmed the biodistribution data. In conclusion, the use
of a triglutamyl spacer is a convenient way to improve the biodistribution profile of Affibody molecules labeled at the N-terminus using 18 F-FBA. It provides at tracer capable of producing high-contrast images of HER2-expressing tumors.
INTRODUCTION
Cancer proliferation, metastasis and neoangiogenesis are often associated with overexpression and excessive signaling of certain transmembrane receptor tyrosine kinases (RTK) 1 . Specific blocking or downregulation of these RTKs is a promising approach to therapy of disseminated cancer. Several RTK-targeting monoclonal antibodies and tyrosine kinase inhibitors have demonstrated improvement of cancer patients' survival and have been approved for routine clinical use. The major issue is, however, the heterogeneity of RTK overexpression. Only a fraction of the patients would have tumors expressing a particular RTK and potentially benefit from a certain treatment. Moreover, expression of RTKs can change during the course of the disease or in response to therapy. As overexpression of a molecular target often is a strong predictive and/or pharmacodynamic biomarker for response to targeting therapy, a noninvasive, repeatable determination of RTK expression levels in tumors would enable personalized therapy of cancer. Radionuclide molecular imaging of RTKs may be a facile method for patient stratification for targeting therapy 2, 3 .
A precondition for the implementation of radionuclide imaging into clinical practice is having high sensitivity and specificity. The use of radiolabeled therapeutic antibodies is a straightforward way for imaging the expression of their molecular targets 4 . However, the long residence time of antibodies in circulation and slow extravasation and tissue penetration cause low tumor-to-organ radioactivity concentration ratios and, consequently, low contrast and sensitivity of imaging using radiolabeled antibodies 3 . Size reduction of targeting proteins is considered as a successful approach for increasing sensitivity of radionuclide imaging 5 . Both experimental data and theoretical calculation predict that molecular weights below 25 kDa in combination with high (at least low nanomolar) affinity are preconditions for successful targeting 6 . This prompts to seek an alternative to immunoglobulins as targeting agents.
A promising class of non-immunoglobulin based targeting proteins are Affibody molecules;
small (7kDa), three-helix proteins based on the B-domain of protein A 7 . Currently, Affibody molecules with low nanomolar or subnanomolar affinity to several RTKs, e.g. HER2 8 , EGFR 9 , HER3 10 , PDGFR  and IGF1R 12 , have been developed. Radiolabeled derivatives of the anti-HER2 Z HER2:342 Affibody molecule have demonstrated the capacity of high contrast imaging of HER2-expressing tumors a few hours after injection both in preclinical studies 13 and in clinical trials 14, 15 . Preclinical data suggest that derivatives of Z HER2:342 provide the highest contrast (sensitivity) and specificity among all evaluated HER2 imaging agents 13 .
Importantly, preclinical data demonstrated that different labeling approaches appreciably influence the biodistribution and targeting properties of Affibody molecules, and a careful optimization of the combination of nuclide and chelator or linker is required to obtain maximum imaging contrast 16 .
The use of positron-emitting labels should enable PET imaging and further increase the sensitivity of Affibody-mediated imaging. This is important for detection of expression in small metastases. The use of PET allows also an accurate quantification of uptake in tumor. 28 ( Figure 1 ). Both approaches include a minimal number of synthetic steps with radiolabeled precursors. AlF chemistry provides residualizing labels, and is the most suitable for peptides that are rapidly internalized after binding to cancer cells.
However, as internalization of the majority of anti-RTK Affibody molecules is slow 9,12,22 , non-residualizing labels can be applied for their labeling without decreasing tumor uptake.
In fact, 18 F-fluorobenzaldehyde conjugation has been used for labeling of recombinant dimeric 19 and monomeric 29 anti-HER2 Affibody molecules (after conjugation of 2-
terminal cysteine) and a synthetic, truncated 2-helix variant of the anti-HER2 Affibody molecules 30 . All conjugates were capable of specific targeting of HER2-expressing xenografts in mice. However, a major concern in all cases was an elevated uptake of radioactivity in liver (close to or even exceeding uptake in tumors at 1-3 h pi), which would prevent imaging of liver metastases in clinics. Taking into account that liver is a major metastatic site for many tumors 31 , this is a serious issue. It has to be noted that the elevated liver uptake of 18 F-N-(4-fluorobenzylidine)oxime (FBO)-labeled Affibody molecules is associated with the labeling methods and not features of the Affibody molecules, as the same targeting proteins had several fold lower hepatic uptake when labeled by other methods 18, 22, 32 . Furthermore, an elevated hepatic uptake or hepatobiliary excretion is often associated with either overall or local elevated lipophilicity of the protein surface 33 . Earlier, we have succeeded in the suppression of hepatic uptake or hepatobiliary excretion of Affibody molecules labeled with 99m
Tc at the N-terminus by increasing the hydrophilicity of the peptide-based chelators via incorporation of glutamyl residues 34, 35 .
Our hypothesis was that incorporation of a triglutamyl spacer between the aminooxy Biodistribution of radiofluorinated variants was evaluated in normal mice to investigate the influence of the triglutamyl linker on hepatic uptake. In addition, targeting of HER2-expressing SKOV-3 xenografts using 18 F-FBO-E 3 -PEP4313 was studied in immunodeficient mice by direct ex vivo measurements and microPET/CT imaging.
MATERIAL AND METHODS

Peptide synthesis
The two Affibody molecules were based on the same core protein,PEP4313, where the only difference is a linker composed of three glutamate residues (E 3 ) introduced at the N-terminus (Figure 2 ).
The two molecules were synthesized using microwave-assisted solid phase peptide synthesis (SPPS). The assembly was performed on a fully automated peptide synthesizer with an integrated microwave oven (Liberty, CEM Corporation) as described earlier 36 . However, the Rink Amide MBHA LL resin (01-64-0467, Merck KGaA) was used in the current study.
For deprotection, a 5% piperazine solution in N-methyl-2-pyrrolidone (NMP) was used with microwave irradiation. A 0.1 mmol batch was synthesized up to the first alanine (A1).
Thereafter, the batch was split into two equal parts to prepare two different variants. At this stage, the triglutamyl (E3)-linker and the final, bis-Boc-protectedaminooxyacetic acid (BB-AOA) residue were attached using manual peptide synthesis. Briefly, the couplings were performed using 5 times molar excess of carboxylic acid. 9- were recovered using ether precipitation and finally freeze-dried before further purification.
Purification and analysis
The crude peptides were purified on an Agilent 1100 HPLC system, using reversed phase HPLC (RP-HPLC). The purification was performed on a Zorbax 300SB C18 (9.4x250, 5 µm) column using 0.1% TFA/H 2 O and 0.1% TFA/CH 3 CN as solvents A and B, respectively. The column oven temperature was set to 30°C. The column was eluted with a linear gradient of 25
-30% solvent B in 3 column volumes (CV) with flow rate of 5 mL/min. UV detection was at 220 and 280 nm. 300 µL fractions were collected using an automated fraction collector. The fractions were analyzed on an Agilent 6500 Series Accurate-Mass Q-TOF LC/MS System using Agilent MassHunter Qualitative Analysis software version B.04.00. LC was run using a C4 column with the same buffers as the Agilent 1100 HPLC system. The fractions with correct mass were pooled, aliquoted and freeze-dried. For final purity analysis, one aliquot of each protein was analyzed on the same Agilent 1100 HPLC system as earlier, using a Zorbax 300SB C18 (4.6x150, 3 µm) column eluted with a linear gradient of 5 -50% solvent B in 6
CV with flow rate of 1 mL/min.
It is important to mention that after the free aminooxyacetic acid (scavenger) has been removed, i.e. during and after purification of the peptides, all handling of the peptides was performed in glass or metal vessels, to avoid contact with plastic, which leads to extensive side reactions. Furthermore, organic solvents of high purity, free of contaminating carbonyl compounds, were used.
Conjugation of non-labeled FBA
For analytical purposes and for the development of a labeling protocol, purified aminooxypeptides were conjugated with cold FBA. FBA (Sigma-Aldrich, #128376) was diluted 1000 times in methanol. The freeze-dried Affibody molecules were reconstituted in 0.1% TFA/H 2 O, mixed with the diluted FBA in a molar ratio of 1:100 (Affibody:FBA) and incubated for 30 min at 60ºC. The reverse ratio (i.e. 100:1, Affibody:FBA) was also evaluated to mimic the conditions of the labeling reaction with 18 F-FBA. Analysis was performed using the same LC and LC/MS systems as described earlier.
Circular dichroism (CD)
FBO-E 3 -PEP4313 and FBO-PEP4313 were analyzed by variable temperature measurements from 20 °C to 90 °C at 221 nm as described earlier 37 . A circular dichroism (CD) wavelength scan from 250 nm to 195 nm was collected before and after melting.
Biacore analysis
The equilibrium dissociation constants (K D ) were determined by binding kinetics analysis on a Biacore 2000 instrument as described earlier 37 . The two protein variants were studied after 
Radioactivity measurements
Radioactivity was measured using a dose calibrator VDC-405 (Veenstra Instruments BV, The Netherlands) equipped with an ionization chamber. In animal studies, the radioactivity was measured using an automated gamma-counter with a 3-inch NaI(Tl) detector. The distribution of radioactivity along the ITLC strips was measured on the CycloneTM Storage Phosphor System (Packard) and analyzed using the OptiQuantTM image analysis software (OptiQuant).
Radiolabeling
The semi-preparative HPLC purification was performed with a VWR HPLC system with a VWR LaPrep P110 gradient pump and a LaPrep P311 variable wavelength UV-detector in series with a Bioscan + flow radioactivity detector FC-3600. The semipreparative HPLC purification was carried out on an ACE C18 HL 5 µm 250 x 10 mm column with 40% MeCN in water, flow 5 mL/min. The analytical HPLC analyses were performed using a VWRHitachi LaChrom Elite system with an L-2130 gradient pump, an L-2300 autosampler, and an L-2450 diode-array detector in series with a Bioscan FC-3300 γ flow count radioactivity detector. The product analysis was performed using Zorbax 300SB C18 column calibrated using non-labeled FBO-E3-PEP4313 and FBO-PEP4313. quantitatively (see below). Water (5 mL) was added before further purification.
A final purification and solvent exchange was performed using NAP-5 size-exclusion column, pre-equilibrated and eluted with PBS. The radiochemical purity of the final product was determined by ITLC eluted with acetone:water (80:70). In this system, radiolabeled Affibody molecules remain at application point while fluorobenzaldehyde and fluoride migrates with the solvent front.
In vitro binding specificity and cellular processing
Binding specificity and cellular processing of 18 F-FBO-E 3 -PEP4313 was studied using HER2-expressing ovarian carcinoma SKOV-3 cells (1.6x10 6 receptors/cells 38 ). 18 F-FBO-E 3 -PEP4313 at a protein concentrations of 270 pM was added to 6 dishes (10 6 cells/ dish). A 1000-fold excess of non-labeled recombinant parental Affibody molecule was added to 3 of the petri dishes 5 min before the labeled conjugate to saturate the receptors. The dishes were incubated for 1h in a humidified incubator at 37 °C. The media was collected, the cells were detached using trypsin-EDTA solution, and the radioactivity was measured both in the media and the cell suspension. The percentage of cell-bound radioactivity was calculated for both the pre-saturated and unsaturated cells.
Processing of the 18 F-FBO-E 3 -PEP4313 by SKOV-3 cells during continuous incubation was studied according to a method described and validated by Wållberg and co-workers 39 . The labeled compounds (protein concentration of 1 nM) were added to petri dishes containing 10 6 cells/dish. The cells were incubated at 37°C, in a humidified atmosphere containing 5% CO 2 .
At predetermined time points (1, 2, 3 and 4 h after incubation start), the media from 3 dishes was collected and the cells were washed in ice-cold serum-free medium. The cells were then treated with 0.5 mL 0.2 M glycine buffer containing 4 M urea, pH 2.5, for 5 min on ice. The solution was collected, and the cells were washed additionally with 0.5 mL glycine buffer.
The fractions were pooled together. The radioactivity of the acid wash fractions was considered to be membrane-bound radioactivity. The cells were then incubated at 37°C for at least 30 min with 0.5 mL 1 M NaOH. The alkaline solution was collected and the cell dishes were washed with an additional 0.5 mL NaOH and the alkaline fractions were pooled. The radioactivity in the alkaline fractions was considered as internalized. A percentage of the internalized radioactivity was calculated for each fraction at each time point.
Biodistribution studies
The animal study was approved by the Local Ethics Committee for Animal Research. The animals were acclimatized for one week at the Rudbeck laboratory animal facility before experiments.
For comparative biodistribution study, normal female NMRI mice were used. An average (60 kBq/mouse, 1 µg/mouse). These mice were sacrificed at 2 h after injection. The biodistribution was measured as described above.
Imaging
To confirm the capacity of 18 F-FBO-E 3 -PEP4313 to image HER2-expressing tumors, two mice bearing SKOV-3 xenografts were intravenously injected with 2.5 MBq of 18 F-FBO-E 3 -PEP4313 (3.3 µg peptide). Immediately before imaging (1 or 2 h pi), the animals were euthanized and the urine bladders were dissected. The PET/CT imaging was performed in The
Triumph™ Trimodality system (Gamma Medica, Inc), a fully integrated SPECT/PET/CT hardware and software platform optimized for small animals. The PET data was reconstructed into a static image using a MLEM 2D algorithm (10 iterations). The CT raw file was reconstructed using Filter Back Projection (FBP). PET and CT dicom-files were analyzed using PMOD v 3.12 software (PMOD Technologies Ltd, Zurich, Switzerland).
RESULTS
Peptide Synthesis
Aminooxy derivatives of PEP4313 were successfully synthesized using Fmoc solid phase peptide synthesis followed by manual conjugation of Bis-Boc-aminooxyacetic acid with subsequent deprotection. The mass of each peptide was determined by ESI-MS, and the experimentally determined molecular weights correlated well with the theoretically calculated values (Figure 3) . Conjugation of non-labeled FBA provided yields of almost 70 % when an excess of FBA was used. After a simple size-exclusion chromatography using a disposable NAP-5 column no free FBA could be detected. After confirming the molecular weight by mass spectrometry, FBO-PEP4313 and FBO-E 3 -PEP4313 were used as standards for radio-HPLC.
Circular dichroism (CD) spectra of FBO-PEP4313 and FBO-E 3 -PEP4313 before and after heating are presented in Figure 4 . Both conjugates generated very similar spectra typical for alpha-helical structure. The CD-spectra did not show any noticeable difference in secondary structure content before and after heating to 90º C for either of the constructs, indicating accurate refolding after denaturing. The melting point (TM) was determined to be 72 and 73º
C for FBO-PEP4313 and FBO-E 3 -PEP4313, respectively.
Biacore analysis
Using Biacore analysis the binding affinity of FBO-E 3 -PEP4313 to HER2 protein was estimated to be K D =180pM (k a = 2.2x10 6 
Radiolabeling
An unoptimized labeling procedure provided an overall non-decay-corrected yield of 3-5%.
The simple azeotropic evaporation of unreacted are presented in Figure 6 . The processing patterns were typical of Z HER2:342 and its derivatives.
The binding was very rapid, and the uptake plateau was reached within 1 h. The internalization was slow. The internalized fraction of activity was small (5-6% of totally bound activity), and did not increase with time.
Animal study
Data concerning a comparative biodistribution of 18 F-FBO-PEP4313 and 18 F-FBO-E 3 -PEP4313 in NMRI mice at 2 h p.i. are presented in Figure 7 . Both compounds demonstrated a rapid clearance from blood (less than 1 %ID/g at 2 h pi) and the majority of organs and tissues. The radioactivity in the gastrointestinal tract and its content was lower than 4% of the injected radioactivity, which suggests that the hepatobiliary pathway played a minor role in excretion of both radiofluorinated conjugates. The hepatic uptake of 18 F-FBO-E 3 -PEP4313
(1.9 ± 0.1 %ID/g), was 2.7-fold lower (p < 0.5) than the uptake of 18 The biodistribution data for BALB/c nu/nu mice ( Figure 9A ) were in a good agreement with the data for NMRI mice (Figure 7) , taking into account the much smaller size of the tumorbearing mice. Already at 1h after injection, radioactivity was cleared to a high extent from blood and majority of tissues (Figure 9 A) . At the same time, the tumor uptake was 21± 3 % ID/g, and only the uptake in kidneys was higher. At two hours after injection, the tumor uptake (20 ± 2 % ID/g) did not differ significantly from uptake at one hour after injection, but radioactivity was further cleared from blood (3.5-fold reduction), and all other measured organs and tissues. The most pronounced difference, nearly 6-fold, was the reduction of renal uptake. The hepatic uptake was reduced 1.6-fold. This resulted in appreciable increase of tumor-to-organ ratios. At two hours after injection, the tumor-to-blood, tumor-to-liver and tumor-to-kidney ratios were 20 ± 2 , 5.1 ± 0.8, and 3.6 ± 0.6, respectively.
The microPET/CT experiment (Figure 10) confirmed the results of the biodistribution study.
Already at one hour after injection, radioactivity in the tumor and kidneys dominated the image (Figure 10A) , and average liver uptake was ca. 3-fold lower than in the tumor. By two hours after injection (Figure 10B) , the radioactivity was cleared from the kidneys, and the tumor was the only site with pronounced radioactivity accumulation.
Discussion
A steadily increasing amount of scientific data suggests that Affibody molecules is a promising class of targeting proteins, which can be successfully applied for radionuclide imaging of molecular targets for cancer therapy, particularly RTKs (for reviews see 3, 13 ). The combination of the exquisite specificity of the Affibody molecules and the high resolution, sensitivity and quantification accuracy of PET would further improve in vivo imaging of cancer-related molecular abnormalities. The use of 18 F as a label would facilitate translation of Affibody-based imaging agents into clinical practice due to the availability of this nuclide and the good feasibility of regional distribution of radiofluorinated tracers. However, a careful optimization of labeling chemistry and molecular design of Affibody molecules is required to realize the potential of these targeting proteins for radionuclide imaging. Importantly, sensitivity of imaging is dependent on contrast, which is determined by tumor-to-organ ratios.
That is why a reduction of radioactivity uptake in normal organs and tissues is as important as enhancement of uptake in tumors. This study was dedicated to the reduction of radioactivity uptake in liver; an important metastatic site for many cancers.
We have shown earlier that incorporation of amino acids with hydrophilic, preferably negatively charged, side chains into mercaptoacetyl-containing peptide-based chelators for labeling with Tc chelates and 18 F-FBO label conjugated via triglutamate spacer (Figure 11 ). Earlier studies suggested that much smaller differences, e.g. the use of homologous macrocyclic chelators DOTA, NOTA, and NODAGA , had appreciable influence on biodistribution (including hepatic uptake) of Affibody molecules labeled with 111 In and 68 Ga. 37 Thus, achieving of the desirable effect was not given a priory.
This required not only changes in the labeling chemistry, but also biological re-evaluation of modified imaging agents.
The triglutamic acid linker did not reduce the melting point of the protein. The presence of the spacer had no influence on the capacity of FBO-E 3 -PEP4313 to refold after heating to 90º C (Figure 4) . This suggested that rather harsh labeling conditions are still permissible to this protein.
Conjugation of FBA was swift and efficient under the right conditions with low pH and elevated temperatures. However, great care has to be taken in order to prevent the reactive aminooxy-group on the peptides not to produce side reactions in contact with plastics. In our hands, contact with different types of plastics (e.g. polypropylene, PEEK and polyethylene) added a +12 Da adduct to the peptides within an hour. Our hypothesis is that the aminooxygroup reacted with residual formaldehyde on the plastic walls, which would add 12 Da to the total mass after formation of the corresponding oxime. Avoiding any contact with plastics from the first purification to the point of conjugation with FBA seemed to eliminate the side reaction and produce constructs with expected masses according to the theoretical calculations.
Importantly, both FBO-PEP4313 and FBO-E 3 -PEP4313 retained the capacity to bind to HER2 with very high (low picomolar) affinity. Apparently, incorporation of the triglutamyl spacer reduced the on-rate of the binding, which caused increase of the dissociation constant from 49 pM for FBO-PEP4313 to 180 pM for FBO-E 3 -PEP4313. This was not entirely unexpected, as N-terminal modification has earlier caused some modulation of affinity of Affibody molecules 34, 38 . However, our recent study 39 Reduction of the renal uptake was an interesting effect of the spacer. Unlike Affibody molecules labeled using residualizing radiometal labels 22, 23, 32, 35 , the renal retention of 18 F-N-(4-fluorobenzylidine)oxime-labeled Affibody molecules is quite low (Figure 9 ). This is in agreement with data showing rapid clearance of radioactivity from kidneys for other Affibody molecules labeled with 18 F-N-(4-fluorobenzylidine)oxime 19, 29, 30 . This is a strong indication that the Experiments in tumor-bearing mice confirmed that 18 F-FBO-E 3 -PEP4313 can target HER2-expressing xenografts with high specificity (Figure 8) . The tumor uptake appreciably exceeded the hepatic uptake already at 1 h after injection, and renal uptake at 2 h because of radioactivity clearance from these organs (Figures 9 and 10) . The tumor uptake remained unchanged between the two time points, despite the apparent non-residualizing properties of the label. Apparently, this is due to slow internalization of 18 F-FBO-E 3 -PEP4313 by tumor cells (Figure 6) . Table 1 shows a comparison of tumor-to-organ ratios of 18 F-FBO-E 3 -PEP4313 with tumor-to-organ ratios of 68 Ga-DOTA-Z HER2:342 anti-HER2 Affibody molecule 22 in BALB/C nu/nu mice bearing SKOV-3 xenografts at 2 h p.i. 68 Ga-DOTA-Z HER2:342 has demonstrated a capacity for a high-contrast imaging of HER2-expressing breast cancer metastases in clinics 14 . Apparently, the tumor-to-organ ratios of 18 F-FBO-E 3 -PEP4313 were quite similar to those of a radiometal-labeled counterpart having the highly hydrophilic DOTA chelator at the N-terminus. The renal uptake of 18 F-FBO-E 3 -PEP4313 is nearly 100-fold lower, which resulted in much higher tumor-to-kidney ratio for the radiofluorinated tracer.
This comparison suggests that 18 F-FBO-E 3 -PEP4313 has a favorable biodistribution profile for radionuclide imaging in vivo.
In conclusion, the introduction of a triglutamyl linker between N-(4-fluorobenzylidine)oxime and the N-terminus of Affibody molecules provides a conjugate with a high (low picomolar) affinity. In mice, both hepatic and renal uptake of 18 
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest. 
